T4-AAV Hybrid Viral Vector for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vectors, both eukaryotic and prokaryotic, face limitations in efficiently delivering genes and proteins into human cells due to restricted capacity, tropism, toxicity, and safety concerns, making them unsuitable for broad application in gene therapy and research.
Innovation Solution
A hybrid viral vector, T4-AAV, is created by attaching adeno-associated virus (AAV) to bacteriophage T4 using avidin-biotin cross-bridges, enhancing the delivery efficiency of genes and proteins into mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If eukaryotic viral vectors (e.g., AAV) are used for gene delivery, then delivery efficiency into mammalian cells is improved, but cargo capacity is limited
Solution Approach 1:
The patent merges the advantages of prokaryotic viruses (large cargo capacity of T4 bacteriophage) and eukaryotic viruses (efficient mammalian cell entry of AAV) by creating a hybrid viral vector where AAV particles are attached to the surface of T4 bacteriophage heads through avidin-biotin crossbridges, enabling both high delivery efficiency and large cargo capacity
2Quantity of substance
If prokaryotic viral vectors (e.g., bacteriophage T4) are used for gene delivery, then cargo capacity is improved, but delivery efficiency into mammalian cells deteriorates
Solution Approach 1:
The patent combines T4 bacteriophage (prokaryotic virus with large cargo capacity) with AAV (eukaryotic virus with efficient mammalian cell tropism) to create a hybrid vector that inherits the large cargo capacity of T4 and the efficient delivery capability of AAV
Solution Approach 2:
The patent uses avidin-biotin crossbridges as intermediary molecules to attach AAV particles to the surface of T4 bacteriophage heads, enabling the prokaryotic virus to efficiently deliver genetic cargo into eukaryotic mammalian cells by leveraging AAV's cell entry mechanisms
3Productivity
If viral vectors are used for gene delivery, then delivery efficiency is improved, but safety concerns and toxicity increase
Solution Approach 1:
The hybrid T4-AAV vector combines the safety profile of non-pathogenic T4 bacteriophage (which cannot replicate in mammalian cells) with the controlled transduction capability of AAV, reducing uncontrolled replication and immune responses while maintaining efficient delivery
Solution Approach 2:
The avidin-biotin crossbridge system provides a controlled, reversible attachment mechanism that allows precise control over vector-cell interactions, reducing unintended toxicity while maintaining high delivery efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The T4-AAV hybrid vector significantly increases gene and protein delivery efficiency, achieving up to 40,000-fold improvement compared to T4 alone, with sustained expression and long-term persistence in vivo, while maintaining cell viability and inducing robust immune responses.
Implementation Method 1
attaching one end of the cross-bridge (Soc or Hoc) to the first virus (bacteriophage T4); and attaching the other end of the cross-bridge (avidin) to the second virus (AAV)
Data Source
AI summary
Described is hybrid viral vector comprising: a first virus such as bacteriophage T4; one or more second virus such as adeno-associated virus (AAV) attached to the first virus through cross-bridges, such as avidin-biotin cross-bridges; one or more DNA molecules packaged in the first virus; one or more nucleic acid molecules packaged in the second virus; and one or more proteins displayed on the surface of the first virus. Also described are methods of making and using such a hybrid viral vector.